tradingkey.logo

PharmaCyte Biotech Inc

PMCB

1.000USD

0.000
Horarios del mercado ETCotizaciones retrasadas 15 min
6.90MCap. mercado
1.08P/E TTM

PharmaCyte Biotech Inc

1.000

0.000
Más Datos de PharmaCyte Biotech Inc Compañía
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
Información de la empresa
Símbolo de cotizaciónPMCB
Nombre de la empresaPharmaCyte Biotech Inc
Fecha de salida a bolsaSep 11, 2003
Director ejecutivoMr. Joshua N. (Josh) Silverman
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 11
Dirección3960 Howard Hughes Parkway, Suite 500
CiudadLAS VEGAS
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal89169
Teléfono19175952850
Sitio Webhttps://pharmacyte.com/
Símbolo de cotizaciónPMCB
Fecha de salida a bolsaSep 11, 2003
Director ejecutivoMr. Joshua N. (Josh) Silverman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
50.00K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 13 de may
Actualizado: mar., 13 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Intracoastal Capital, L.L.C.
7.68%
The Vanguard Group, Inc.
2.83%
Geode Capital Management, L.L.C.
2.02%
Equitec Proprietary Markets, LLC
1.21%
Asher (Daniel B)
1.21%
Other
85.05%
Accionistas
Accionistas
Proporción
Intracoastal Capital, L.L.C.
7.68%
The Vanguard Group, Inc.
2.83%
Geode Capital Management, L.L.C.
2.02%
Equitec Proprietary Markets, LLC
1.21%
Asher (Daniel B)
1.21%
Other
85.05%
Tipos de accionistas
Accionistas
Proporción
Corporation
7.68%
Investment Advisor
4.57%
Individual Investor
2.85%
Investment Advisor/Hedge Fund
2.60%
Hedge Fund
1.14%
Bank and Trust
0.05%
Other
81.10%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
66
1.30M
18.90%
-536.38K
2025Q1
71
1.30M
18.90%
-631.78K
2024Q4
75
1.52M
21.80%
-704.25K
2024Q3
81
1.75M
23.16%
-1.87M
2024Q2
84
1.91M
21.34%
-3.77M
2024Q1
81
1.85M
20.70%
-3.82M
2023Q4
82
1.98M
21.84%
-3.87M
2023Q3
81
2.90M
23.35%
-2.45M
2023Q2
83
2.99M
16.94%
-4.58M
2023Q1
79
7.49M
40.43%
+256.98K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Intracoastal Capital, L.L.C.
527.38K
7.68%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
194.52K
2.83%
+2.13K
+1.11%
Mar 31, 2025
Geode Capital Management, L.L.C.
138.94K
2.02%
-25.80K
-15.66%
Mar 31, 2025
Equitec Proprietary Markets, LLC
82.73K
1.21%
--
--
Mar 31, 2025
Asher (Daniel B)
82.73K
1.21%
--
--
Dec 31, 2024
Schechter (Jonathan L)
50.00K
0.73%
--
--
Feb 01, 2025
Silverman (Joshua N.)
50.00K
0.73%
--
--
Feb 01, 2025
Renaissance Technologies LLC
49.50K
0.72%
+200.00
+0.41%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
25.50K
0.37%
-200.00
-0.78%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
20.30K
0.3%
-6.54K
-24.37%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI